Abeona Therapeutics Appoints Keith A. Goldan to Board of Directors and Audit Committee Chair

On April 1, 2026, Abeona Therapeutics Inc. expanded its Board of Directors from nine to ten members and appointed Keith A. Goldan as an independent Class 1 director. Mr. Goldan will also serve as the Chair of the Audit Committee. His term is set to expire at the Company’s 2026 annual meeting of stockholders. Mr. Goldan brings over 20 years of financial leadership experience in the biotechnology and pharmaceutical industries, currently serving as CFO of Syndax Pharmaceuticals and having previously held CFO roles at Optinose and Fibrocell. As part of his compensation, Mr. Goldan will receive an annual cash fee of $50,000 and a one-time sign-on equity grant of $150,000 in restricted stock awards with a one-year vesting period. He will be eligible for regular annual equity grants starting in 2027. The appointment is intended to strengthen Abeona's financial and strategic leadership as it transitions into a commercial-stage company following the development of ZEVASKYN®, its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).